Hence we sought to comprehensively investigate the role of KLK4 in prostate cancer risk and tumour aggressiveness by genotyping the majority of validated genetic variation (±10 kb) around the KLK4 locus in a large prostate cancer study group and male controls not screened for PSA levels. This evidence concerns the gene KLK4 and neoplasm.